William P. Kane Jr. - 16 Aug 2021 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
Chief Commercial Officer
Signature
/s/ Richard I. Steinhart, as Attorney-in-Fact
Issuer symbol
BTAI
Transactions as of
16 Aug 2021
Net transactions value
$0
Form type
4
Filing time
18 Aug 2021, 17:25:50 UTC
Next filing
07 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Stock Option (Right to Buy) Award $0 +40,000 $0.000000 40,000 16 Aug 2021 Common Stock 40,000 $23.84 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of August 16, 2021 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person'scontinuous employment with the Issuer through the relevant vesting dates.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney